The disabled men were continually subjected to taunts and weren't provided adequate medical care during their 20 years at the Iowa meatpacking plant.
Three of Australia’s largest coal-fired power generators have committed to building test facilities adjacent to their power stations, where smoke-stack CO2 emissions are captured and used to grow oil-rich algae in solar bioreactors.
Japanese manufacturer narrowed its annual loss from record red ink the previous year and forecast it would return to profit for the first time in five years.
Boeing workers who assemble the giant C-17 cargo jets in Long Beach are on picket lines in a dispute over pension and medical benefits.
Government could get back $40 billion of its $50 billion investment in General Motors, and difference would be well spent because it prevented mass job losses, Steven Rattner said.
Cell phone maker is reorganizing its leadership to tackle growing competition from rivals in smart phones and high-end mobile computers.
Two former underage workers testified against their former manager, who faces 83 child labor violation charges stemming from a May 2008 raid at the plant in which 389 illegal immigrants, including 31 children, were detained.
Executives from BP, Halliburton and Transocean are trying to shift responsibility to each other.
The EPA administrator is meeting with LSU scientists to discuss the state's concerns about the potential longterm effects.
World?s top carmaker cruised back to profit in latest quarter as the company cut costs and hitched a ride on the global auto sales recovery while fighting to salvage its reputation.
Manufacturing output in March was 3.3 percent higher than a year ago and 2.3 percent better than the previous month, U.K. government statisticians said.
South Korean conglomerate to invest $20.6 billion in technologies including solar cells and medical devices, aiming to boost sales and increase its work force by tens of thousands.
GlaxoSmithKline says it has signed a strategic alliance with South Korea's Dong-A Pharmaceuticals, acquiring a 9.9 percent stake for $109.5 million.
Drug and medical device maker Abbott Laboratories is licensing the products from Zydus Cadila, based in India, and will sell them in 15 emerging markets through a new unit.